Cargando…

Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis

Teriparatide is a new agent serves as a treatment of choice for severe post-menopausal osteoporotic patients who are at high risk of fracture or have failed or been intolerant of previous osteoporosis therapy. The objective of this study is to estimate the cost-utility of teriparatide compared with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taheri, Saeed, Mirzayeh Fashami, Fatemeh, Peiravian, Farzad, Yousefi, Nazila
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Shaheed Beheshti University of Medical Sciences 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706718/ https://www.ncbi.nlm.nih.gov/pubmed/31531089 http://dx.doi.org/10.22037/ijpr.2019.1100679

Ejemplares similares

Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost–Utility Analysis from the Canadian Public Payer’s Perspective
por: Mirzayeh Fashami, Fatemeh, et al.
Publicado: (2023)

Profile of teriparatide in the management of postmenopausal osteoporosis
por: Sikon, Andrea, et al.
Publicado: (2010)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Systematic Review and Meta-analysis in Patients with Type 2 Diabetes Mellitus
por: Taheri, Saeed, et al.
Publicado: (2019)

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
por: Sun, Yang, et al.
Publicado: (2022)

Vertebral Collapse Prevented Following Teriparatide Treatment in Postmenopausal Kümmell's Disease Patients with Severe Osteoporosis
por: Gou, Peng‐guo, et al.
Publicado: (2021)

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden
por: Murphy, Daniel R, et al.
Publicado: (2012)

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
por: Darbà, Josep, et al.
Publicado: (2015)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials
por: Wang, Ya-Kang, et al.
Publicado: (2017)

Impact of the Trade-Related Aspect of Intellectual Property Rights Agreement on Pharmaceutical Industry in Developing Countries: A Scoping Review
por: Fathi, Mahdieh, et al.
Publicado: (2021)

How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements?
por: Shobeiri, Nikta, et al.
Publicado: (2022)

Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide
por: Reginster, Jean-Yves, et al.
Publicado: (2018)

Teriparatide in the management of osteoporosis
por: Bodenner, Donald, et al.
Publicado: (2007)

Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study
por: Ljunggren, Östen, et al.
Publicado: (2013)

Treatment of osteoporosis with teriparatide: The Slovenian experience
por: Kocjan, Tomaz, et al.
Publicado: (2021)

How does external reference pricing work in developing countries: evidence from Iran
por: Babaie, Fatemeh, et al.
Publicado: (2023)

Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis
por: Satterwhite, Julie, et al.
Publicado: (2010)

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
por: Sugimoto, T., et al.
Publicado: (2014)

Effect of teriparatide on quality of life in patients with postmenopausal osteoporosis: a retrospective cohort study
por: Yang, Tiansong, et al.
Publicado: (2019)

Impact of teriparatide therapy in Indian postmenopausal women with osteoporosis with regard to DXA-derived parameters
por: Sandeep, Nandipati Venkata, et al.
Publicado: (2022)

Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
por: Li, Mei, et al.
Publicado: (2022)

Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis
por: Weigl, Moritz, et al.
Publicado: (2021)

Utility of radius bone densitometry for the treatment of osteoporosis with once-weekly teriparatide therapy
por: Nakayama, Harumi, et al.
Publicado: (2018)

THU441 Teriparatide As Treatment For Severe Osteoporosis In Lung Transplant Recipients
por: Muir, Christopher Alan, et al.
Publicado: (2023)

The Effect of Organizational Resilience and Strategic Foresight on Firm Performance: Competitive Advantage as Mediating Variable
por: Fathi, Mahdieh, et al.
Publicado: (2021)

Exploring health seeking behaviors for common cold management
por: Keshvari, Negin, et al.
Publicado: (2023)

Teriparatide – Indications beyond osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2012)

Therapy of Osteoporosis in Men with Teriparatide
por: Cusano, Natalie E., et al.
Publicado: (2011)

Role of teriparatide in treatment of glucocorticoid-induced osteoporosis
por: Lau, Arthur N, et al.
Publicado: (2010)

Update on the safety and efficacy of teriparatide in the treatment of osteoporosis
por: Minisola, Salvatore, et al.
Publicado: (2019)

Romosozumab versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta‐analysis through a Grade Analysis of Evidence
por: Tian, Aixian, et al.
Publicado: (2021)

Teriparatide treatment for postmenopausal women with sacral insufficiency fracture
por: Kim, Young-Hoon
Publicado: (2023)

Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis
por: Fan, Guiyong, et al.
Publicado: (2020)

The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: A protocol for systematic review and meta-analysis
por: Ouyang, YuLong, et al.
Publicado: (2021)

Treatment responses with once-weekly teriparatide therapy for osteoporosis
por: Shiraki, M., et al.
Publicado: (2016)

Teriparatide for osteoporosis: importance of the full course
por: Lindsay, R., et al.
Publicado: (2016)

How Much Iranian Parents Know of and How Well They Practice Regarding Antibiotics?
por: Sharif, Zahra, et al.
Publicado: (2021)

An investigation into the pharmaceutical advertising in Iranian medical journals
por: Yousefi, Nazila, et al.
Publicado: (2022)

Evaluating the affordability of asthma, chronic obstructive pulmonary disease, and cystic fibrosis medicines in a middle-income country
por: Fathi, Mahdieh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9h1l6i7anofrr8hasu0lpj8sr7